Replies to post #1097 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

It used to be 15 months (or 64 weeks). 59 weeks (almost 14 months) is 5 weeks less. Do you recall why the numbers changed?

http://www.vblrx.com/vbl-therapeutics-announces-launch-of-the-first-israeli-site-as-part-of-the-globe-international-pivotal-trial-for-vb-111/

In November 2015, at the Society for Neuro-Oncology (SNO) conference, VBL reported data from its recently-completed Phase 2 multi-center study of VB-111 in rGBM, which showed that VB-111 almost doubled the historical median overall survival for rGBM. Patients treated with continuous exposure of VB-111 had median overall survival (OS) of 15 months, compared to 8 months in patients with limited VB-111 exposure (p=0.048).